Literature DB >> 9816205

Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms.

I M Shih1, T L Wang, W H Westra.   

Abstract

Mel-CAM (previously MUC18) is an integral membrane glycoprotein involved in heterophilic intercellular adhesions. Mel-CAM is expressed specifically in certain normal mesenchymal tissues, including smooth muscle, endothelium, and Schwann cells. As a member of the immunoglobulin supergene family of cell adhesion molecules (CAMs), Mel-CAM may play a pivotal role in the normal differentiation and functional activity of these tissues. To determine the distribution of Mel-CAM in mesenchymal neoplasms and to investigate its potential role as a factor in tumor progression, we evaluated a spectrum of mesenchymal neoplasms by immunohistochemistry using a Mel-CAM-specific polyclonal antibody on formalin-fixed tissues. Mel-CAM positivity was observed in 5 (100%) of 5 leiomyomas, 29 (91%) of 32 leiomyosarcomas, 5 (100%) of 5 hemangiomas, 5 (100%) of 5 angiosarcomas, 3 (100%) of 3 Kaposi's sarcomas, 8 (100%) of 8 schwannomas, 10 (100%) of 10 neurofibromas, 0 (0%) of 8 malignant peripheral nerve sheath tumors, 2 (15%) of 13 malignant fibrous histiocytomas, 0 (0%) of 8 fibrosarcomas, 0 (0%) of 7 synovial sarcomas, and 0 (0%) of 6 liposarcomas. These results show that Mel-CAM is expressed consistently in neoplasms of smooth muscle and vascular origin, and that immunostaining for Mel-CAM may serve as a useful adjunct in differentiating leiomyosarcomas, angiosarcomas, and Kaposi's sarcomas from other spindle cell neoplasms. Furthermore, the observation that Mel-CAM is expressed consistently in schwannomas and neurofibromas but not in malignant peripheral nerve sheath tumors implicates Mel-CAM as a potential modulator of malignant transformation in peripheral nerve tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816205

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Benign mesenchymal stromal cells in human sarcomas.

Authors:  Alexei Morozov; Robert J Downey; John Healey; Andre L Moreira; Emil Lou; Anna Franceschino; Yildirim Dogan; Roland Leung; Mark Edgar; Michael LaQuaglia; Robert G Maki; Malcolm A S Moore
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

2.  The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma.

Authors:  L M Shih; M Y Hsu; J P Palazzo; M Herlyn
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

3.  Expression and distribution of MUC18 in human uveal melanoma.

Authors:  Kenneth Lai; Vidushi Sharma; Martine J Jager; R Max Conway; Michele C Madigan
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

4.  Reduced CD146 expression promotes tumorigenesis and cancer stemness in colorectal cancer through activating Wnt/β-catenin signaling.

Authors:  Dan Liu; Lei Du; Dong Chen; Zhongde Ye; Hongxia Duan; Tao Tu; Jing Feng; Yili Yang; Quan Chen; Xiyun Yan
Journal:  Oncotarget       Date:  2016-06-28

Review 5.  CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target.

Authors:  Ayobami Matthew Olajuyin; Adefunke Kafayat Olajuyin; Ziqi Wang; Xingru Zhao; Xiaoju Zhang
Journal:  Cancer Cell Int       Date:  2019-09-26       Impact factor: 5.722

6.  Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours.

Authors:  Arash Rafii; Pejman Mirshahi; Mary Poupot; Anne-Marie Faussat; Anne Simon; Elodie Ducros; Eliane Mery; Bettina Couderc; Raphael Lis; Jerome Capdet; Julie Bergalet; Denis Querleu; Francoise Dagonnet; Jean-Jacques Fournié; Jean-Pierre Marie; Eric Pujade-Lauraine; Gilles Favre; Jeanine Soria; Massoud Mirshahi
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.